127 related articles for article (PubMed ID: 30311125)
1. Novel combination of tanshinone I and lenalidomide induces chemo-sensitivity in myeloma cells by modulating telomerase activity and expression of shelterin complex and its associated molecules.
Kumar R; Gupta N; Himani ; Sharma A
Mol Biol Rep; 2018 Dec; 45(6):2429-2439. PubMed ID: 30311125
[TBL] [Abstract][Full Text] [Related]
2. Tanshinone IIA combined with adriamycin inhibited malignant biological behaviors of NSCLC A549 cell line in a synergistic way.
Xie J; Liu JH; Liu H; Liao XZ; Chen Y; Lin MG; Gu YY; Liu TL; Wang DM; Ge H; Mo SL
BMC Cancer; 2016 Nov; 16(1):899. PubMed ID: 27863471
[TBL] [Abstract][Full Text] [Related]
3. A Polyherbal Ashwagandha Formulation Exhibits Adjunctive Antitumor Efficacy Against U266 Myeloma Cells by Multi-Strategic Cytotoxic Effects: An Experimental Approach.
Kapoor S; Gupta N; Sharma A
Asian Pac J Cancer Prev; 2023 Nov; 24(11):3705-3714. PubMed ID: 38019228
[TBL] [Abstract][Full Text] [Related]
4. Habb-e-Asgandh Suppresses Cell Proliferation and Induces Apoptosis through Mitochondria Dysfunction in Multiple Myeloma Cells (RPMI8226).
Vashist A; Gupta N; Nafees S; Sharma A
Asian Pac J Cancer Prev; 2022 Nov; 23(11):3629-3639. PubMed ID: 36444574
[TBL] [Abstract][Full Text] [Related]
5. Identifying the biomarker potential of telomerase activity and shelterin complex molecule, telomeric repeat binding factor 2 (TERF2), in multiple myeloma.
Kumar R; Khan R; Gupta N; Seth T; Sharma A; Kalaivani M; Sharma A
Leuk Lymphoma; 2018 Jul; 59(7):1677-1689. PubMed ID: 29043869
[TBL] [Abstract][Full Text] [Related]
6. Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma.
Shammas MA; Shmookler Reis RJ; Akiyama M; Koley H; Chauhan D; Hideshima T; Goyal RK; Hurley LH; Anderson KC; Munshi NC
Mol Cancer Ther; 2003 Sep; 2(9):825-33. PubMed ID: 14555701
[TBL] [Abstract][Full Text] [Related]
7. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
[TBL] [Abstract][Full Text] [Related]
8. Influence of Tanshinone IIA on the Apoptosis of Human Esophageal Ec-109 Cells.
Zhu YQ; Wang BY; Wu F; An YK; Zhou XQ
Nat Prod Commun; 2016 Jan; 11(1):17-9. PubMed ID: 26996008
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib-mediated down-regulation of telomerase and disruption of telomere homeostasis contributes to apoptosis of malignant cells.
Ci X; Li B; Ma X; Kong F; Zheng C; Björkholm M; Jia J; Xu D
Oncotarget; 2015 Nov; 6(35):38079-92. PubMed ID: 26472030
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between Beclin-1-dependent autophagy and caspase‑dependent apoptosis induced by tanshinone IIA in human osteosarcoma MG-63 cells.
Ma K; Zhang C; Huang MY; Guo YX; Hu GQ
Oncol Rep; 2016 Oct; 36(4):1807-18. PubMed ID: 27499329
[TBL] [Abstract][Full Text] [Related]
11. Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma.
Shammas MA; Shmookler Reis RJ; Li C; Koley H; Hurley LH; Anderson KC; Munshi NC
Clin Cancer Res; 2004 Jan; 10(2):770-6. PubMed ID: 14760100
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma.
van der Spek E; Bloem AC; Lokhorst HM; van Kessel B; Bogers-Boer L; van de Donk NW
Leuk Res; 2009 Jan; 33(1):100-8. PubMed ID: 18621417
[TBL] [Abstract][Full Text] [Related]
13. Differential Expression of Non-Shelterin Genes Associated with High Telomerase Levels and Telomere Shortening in Plasma Cell Disorders.
Panero J; Stella F; Schutz N; Fantl DB; Slavutsky I
PLoS One; 2015; 10(9):e0137972. PubMed ID: 26366868
[TBL] [Abstract][Full Text] [Related]
14. HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
Canella A; Cordero Nieves H; Sborov DW; Cascione L; Radomska HS; Smith E; Stiff A; Consiglio J; Caserta E; Rizzotto L; Zanesi N; Stefano V; Kaur B; Mo X; Byrd JC; Efebera YA; Hofmeister CC; Pichiorri F
Oncotarget; 2015 Oct; 6(31):31134-50. PubMed ID: 26429859
[TBL] [Abstract][Full Text] [Related]
15. Silencing of telomere-binding protein adrenocortical dysplasia (ACD) homolog enhances radiosensitivity in glioblastoma cells.
Polito F; Cucinotta M; Abbritti RV; Brogna A; Pergolizzi S; Tomasello C; Barresi V; Angileri FF; Di Giorgio R; Conti A; La Torre D; Germanò A; Aguennouz M
Transl Res; 2018 Dec; 202():99-108. PubMed ID: 30080989
[TBL] [Abstract][Full Text] [Related]
16. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
Jiao JW; Wen F
Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580
[TBL] [Abstract][Full Text] [Related]
17. SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide.
Du L; Liu W; Pichiorri F; Rosen ST
Cancer Gene Ther; 2023 Apr; 30(4):567-574. PubMed ID: 35338347
[TBL] [Abstract][Full Text] [Related]
18. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.
Rychak E; Mendy D; Shi T; Ning Y; Leisten J; Lu L; Miller K; Narla RK; Orlowski RZ; Raymon HK; Bjorklund CC; Thakurta A; Gandhi AK; Cathers BE; Chopra R; Daniel TO; Lopez-Girona A
Br J Haematol; 2016 Mar; 172(6):889-901. PubMed ID: 26914976
[TBL] [Abstract][Full Text] [Related]
19. Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma.
Tang S; Ma D; Cheng B; Fang Q; Kuang X; Yu K; Wang W; Hu B; Wang J
Exp Cell Res; 2018 Feb; 363(2):196-207. PubMed ID: 29317217
[TBL] [Abstract][Full Text] [Related]
20. Influence of Tanshinone IIA on apoptosis of human esophageal carcinoma Eca-109 cells and its molecular mechanism.
Zhang Y; Li S; He H; Han Q; Wang B; Zhu Y
Thorac Cancer; 2017 Jul; 8(4):296-303. PubMed ID: 28407361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
